Off-Label Drug Uses — This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration (FDA). This new guide to the literature will enable the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. A summary of the most relevant data is provided, including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to hospitalpharmacy@wolterskluwer.com.
Get full access to this article
View all access options for this article.
References
1.
SilbersteinS.D.Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.2000; 55(6): 754–762.
2.
BenderW.I.ACE inhibitors for prophylaxis of migraine headaches. Headache.1995; 35(8): 470–471.
3.
EtminanM., LevineM.A., TomlinsonG., RochonP.A.Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am J Med.2002; 112(8): 642–646.
4.
CharlesJ.A., JotkowitzS., ByrdL.H.Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache.2006; 46(3): 503–507.
5.
OwadaK.Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens Res.2004; 27(6): 441–446.
TronvikE., StovnerL.J., HeldeG., SandT., BovimG.Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA.2003; 289(1): 65–69.
